



Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

September 1, 2026

BRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m. ET.

The live webcast will be available to investors and other interested parties by accessing the [Investor Relations](#) section of the Legend Biotech website. The webcast replay will be available approximately 48 hours after the webcast.

ABOUT LEGEND BIOTECH

With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI[®], a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI's patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at www.legendbiotech.com and follow us on [X](#), [Instagram](#), and [LinkedIn](#).

INVESTOR CONTACT:

Caroline Paul

Tel: (973) 650-5832

Caroline.Paul@legendbiotech.com

PRESS CONTACT:

Kim Fox

Tel: (848) 388-8445

media@legendbiotech.com

